Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6 Neoplasms 3 Lung Neoplasms 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pleural Effusion 1 Pituitary Diseases 1 Pituitary ACTH Hypersecretion 1 Obesity 1 Myasthenia Gravis 1 Motor Activity 1 Lymphoma 1 Kidney Neoplasms 1 Endometrial Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Advanced Solid Tumors 1 Adenocarcinoma of Lung 1 ACTH-Secreting Pituitary Adenoma 1

Interventions

Gemcitabine 83 Cisplatin 53 Oxaliplatin 36 lenvatinib 25 Capecitabine 23 durvalumab 22 Fluorouracil 20 Leucovorin 15 tislelizumab 11 pembrolizumab 11 apatinib 10 Radiotherapy 10 Albumin-Bound Paclitaxel 10 Radiofrequency Ablation 9 Magnetic Resonance Spectroscopy 9 Irinotecan 9 Floxuridine 9 Liver Transplantation 8 Drug Therapy 8 Cholangiopancreatography, Endoscopic Retrograde 8 130-nm albumin-bound paclitaxel 8 Taxes 7 S 1 (combination) 7 Platinum 7 Photochemotherapy 7 Panitumumab 7 Biopsy 7 1,2-diaminocyclohexaneplatinum II citrate 7 tremelimumab 6 pemigatinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Cholangiocarcinoma × Biomarkers × Clear all

NCT02893085 2016-12-28

ONCOBIL

CHU de Reims

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡